Cancer Immunology Research· 2026Q1
Cullin-5 RING E3 ligase limits CD8⁺ T-cell persistence and effector responses during chronic antigen stimulation
- 1citations
- Q1SCImago
- 2026year
Short summary
Disrupting Cullin-5 (CRL5) E3 ligase complexes in CD8+ T cells preserves their cytotoxic activity and cytokine production, enhancing effector function and antitumor responses in a melanoma xenograft model.
AI-generated from the title and abstract; the full text is not read.
Key points
- Genome-wide CRISPR screens revealed Cullin-5 (CRL5) E3 ligase components (CUL5, RNF7, ARIH2) limit CD8+ T-cell persistence.
- Disrupting CRL5 genes preserved T-cell cytotoxic activity and cytokine production while suppressing exhaustion.
- Pharmacologic inhibition of cullin neddylation with MLN4924 mimicked CRL5 loss effects in vitro.
- CRL5-deficient T cells improved tumor control in a human melanoma xenograft model.
AI-generated from the title and abstract; the full text is not read.
Abstract
T-cell exhaustion limits durable antitumor responses and remains a barrier to adoptive cell therapies (ACT) in solid tumors. To identify regulators of T-cell persistence, we performed genome-wide CRISPR knockout screens in primary human CD8⁺ T cells expressing an NY-ESO-1-specific T-cell receptor and subjected them to repeated tumor cell rechallenge. These screens revealed enrichment of single-guide RNAs targeting components of Cullin-RING E3 ligases, particularly Cullin-5 (CRL5) assemblies comprising CUL5, RNF7, and ARIH2. Disruption of CRL5 genes in T cells preserved cytotoxic activity and enhanced cytokine production while sustaining effector-associated transcriptional programs and suppressing exhaustion-related signatures. Pharmacologic inhibition of cullin neddylation with the NEDD8-activating enzyme inhibitor MLN4924 recapitulated CRL5 loss and enhanced T-cell effector function in vitro. In a human melanoma xenograft model, ACT with CRL5-deficient T cells improved tumor control. Together, these findings identify CRL5 as a negative regulator of T-cell fitness and a potential therapeutic target to enhance ACT durability in solid tumors.
The authors' abstract, as published at the source. Cancer Immunology Research, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
ImmunologyImmunology and Microbiology